source
- Biohaven targets muscle-sparing obesity market to compete with Lilly's GLP-1 drugsBiohaven is positioning itself to address obesity by developing treatments that preserve lean muscle, a differentiator from existing GLP-1 therapies. The company sees an opportunity to act as a "s…
- FDA targets online ketamine sellers as health premiums surge, and children 2+ can now obtain CGMs without prescriptionThe Food and Drug Administration is intensifying its enforcement against online retailers that sell ketamine, a controlled substance, citing concerns about unregulated distribution and public safet…